Announcements
from November 30, 20151. Appendix 2 “Specific requirements for the performance audit of prescribed therapeutic products” is changed as follows:
After § 2 Paragraph 4 new Paragraph 5 is added:
“The nationwide special ordinance requirements according to Paragraph 1 as well as the determination of the Federal Joint Committee on the long-term need for medicinal products according to Paragraph 3 are only valid for ordinance periods to be applied from 01/01/2017. For testing periods up to December 31, 2016, however, the agreement on special features of the practice according to Section 84 (8) sentence 3 SGB V, taking into account the long-term need for medicinal products according to Section 32 (1a) SGB V of November 12, 2012 continues.
After § 3, new § 4 is inserted:
"§ 4 Termination
Notwithstanding § 9 Paragraph 1 Clause 1 of these framework specifications, this annex including its appendices can with Term of 6 months to the end of the year, but for the first time on December 31, 2018. Appendix 2 is supplemented by an appendix 1 “Special prescription requirements for therapeutic products according to Section 106b Paragraph 2 Clause 4 SGB V”, which emerges from the annex of this amending agreement.
3. The protocol note for Annex 2 § 2 is omitted.
Berlin, February 15, 2016
GKV-Spitzenverband
National Association of Statutory Health Insurance Physicians
6
0
Do you want a website?